X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Rotavirus Vaccination Decreases Diarrhea Hospitalizations Among Kids

Yuvraj_pawp by Yuvraj_pawp
7th July 2014
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Since the introduction of routine rotavirus vaccination in 2006, rates of diarrhea-related hospitalizations in US children have decreased significantly.

 

Diarrhea-related health care use among young children in the United States has dramatically decreased since the implementation of rotavirus vaccines, the results of a recent study indicate. In addition, the study estimates that more than $900 million in health care costs have been avoided due to vaccination.

 

In 2006, routine vaccination with the pentavalent rotavirus vaccine (RV5) was recommended for infants by the Advisory Committee on Immunization Practices, and the monovalent rotavirus vaccine (RV1) was added to the recommendation in 2008. The current study, published online on June 9, 2014, in Pediatrics, analyzed data from the 2001-2011 Truven Health MarketScan Commercial Claims and Encounters Database to evaluate reductions in diarrhea-associated health care use among children younger than 5 years after the introduction of both vaccines. The retrospective analysis also assessed the direct and indirect effectiveness of the vaccines.

 

The researchers of the study analyzed annual RV5 and RV1 vaccine coverage and compared rates of diarrhea-associated hospitalizations, emergency department visits, and outpatient visits during a pre-vaccine period (2001 to 2006) and during a post-vaccine period (2007 to 2011). Rates of diarrhea-associated health care use were also compared among vaccinated and unvaccinated children, and among unvaccinated children in pre- and post-vaccine periods.

 

By the end of 2010, 58% of children included in the study had been vaccinated with at least 1 dose of RV5 and 5% had received at least 1 dose of RV1. The results indicated that diarrhea-associated hospitalizations were significantly lower for each of the 4 seasons after the vaccines were introduced, and emergency department and outpatient visits were significantly lower in all seasons, except for the 2008-2009 season. Compared with the average rate of hospitalizations for diarrhea from 2001 to 2006, hospitalization rates fell by 75% in 2007-2008, 60% in 2008-2009, 94% in 2009-2010, and 80% in 2010-2011.

 

During the 2010-2012 season, the rate of hospitalizations decreased by 92% among children vaccinated with RV5 and by 96% among those who received RV1 when compared with unvaccinated children. Emergency department visits also significantly declined by 31% among children who received RV5 and by 33% among those who received RV1 when compared with unvaccinated children.  In addition, hospitalization rates among unvaccinated children significantly decreased by 50% in 2007-2008, 77% in 2009-2010, and 25% in 2010-2011 when compared with the average rate during the pre-vaccine period.

 

Overall, the researchers estimated that 176,587 hospitalizations, 242,335 emergency department visits, and 1,116,869 outpatient visits were avoided among children younger than 5 years from 2007 to 2011. Based on these numbers, they estimated that health care costs were reduced by $924 million during this period.

 

“Both rotavirus vaccines showed comparable effectiveness and long-term protection was documented for RV5,” the authors of the study wrote. “Indirect benefits from vaccination were observed and have amplified the overall impact of the vaccination program.” – See more at: http://www.pharmacytimes.com/news/Rotavirus-Vaccination-Decreases-Diarrhea-Hospitalizations-Among-Kids#sthash.mJ38G9hS.dpuf

 

Tags: America
Previous Post

GenOway offers industry scientists immediate access to EUCOMM conditional KO mouse models

Next Post

Weight-Loss Surgery, Prescriptions More Satisfying for Obese Patients

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Glenmark Generics receives final ANDA approval for Telmisartan tablets

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In